🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND)

RecruitingNAAges 18 Years - anyAllRAND
NCT06949774 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Low medication adherence when initiating antiretroviral treatment (ART) is a key barrier to HIV virologic suppression, resulting in avoidable cases of drug resistance, death, and viral transmission. Routinized pill-taking can lead to successful long-term ART adherence, and short-term behavioral economics-based supports are a novel way to overcome the limited success of existing routinization interventions. This study proposes to test this combined approach for promoting long-term ART adherence using a Stage III Sequential, Multiple Assignment, Randomized Trial (SMART) design in one of the largest HIV clinics in Uganda to identify the most cost-effective adaptive intervention that if found effective is generalizable to other settings and other chronic diseases.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Male and female clients age 18 and older. * Started ART at Mildmay or another clinic within the preceding 2 months * Able to speak and understand either English or Luganda. * Have their own cell phone or have consistent access to someone else's phone. * Willing to receive daily text messages for the 6 months of intervention duration. * Willing and able to use the WisePill device distributed for adherence verification for the duration of the study. Exclusion Criteria: * Not mentally fit to consent. * Language other than Luganda or English. * Not willing to consistently use the Wisepill device for adherence measurement.
💊

What it tests

  • Daily Text Messages
  • Incentivization based on timely ART adherence
📍

Where

1 site
Mildmay Uganda
Kampala, Uganda
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy